VR for Symptom Control and Wellbeing

The Use of Virtual Reality for Symptom Control and Wellbeing in Palliative Care and Oncology Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04821466

Enrollment

Registered

2021-03-29

Start date

2021-06-14

Completion date

2022-09-20

Last updated

2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Cancer, Hematologic Malignancy, Oncology, Palliative Care

Keywords

Virtual Reality

Brief summary

To investigate the effect that a Virtual Reality experience can have on patient symptoms and wellbeing for palliative care and oncology inpatients

Interventions

DEVICEVirtual Reality Headset to provide a Virtual Reality Experience

Participants will utilise a Virtual Reality experience for distraction therapy via a Virtual reality headset. Participants will wear the Virtual reality headset to be immersed in a multimedia experience.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Intervention model description

Cohort interrupted time series study

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \> 18 years of age * Inpatient at RCHT know to the palliative care team * Able to consent * Able to speak and understand the English language * Able to use the virtual reality system * Able to complete ESAS-r Questionnaire

Exclusion criteria

* \<18 years of age * Patient unable to consent * Patient unable to speak English * Unable to use the virtual reality system (e.g. visually impaired) * Known Epilepsy or seizures or suspected predisposition to seizures (e.g. Brain metastasis)

Design outcomes

Primary

Measure	Time frame	Description
ESAS-r Quality of Life Scores	Time 0 & Time 60 minutes	Change in ESAS-r QoL score between start and finish of Virtual Reality experience. 0 = No symptoms to 10 = Worst Symptom

Secondary

Measure	Time frame	Description
Quantitative clinician experience of VR intervention	Time 60 minutes	Clinician score of patient experience using Virtual Reality intervention for symptoms and wellbeing between 0 (negative) and 10 (positive)

Other

Measure	Time frame	Description
Qualitative patient experience of VR interventions	Time 60 minutes	Patients to answer: Were there any negative side effects of the VR session?
Repeat VR experiences	12 Months	ESAS-r QoL Scores (0 to 10) will be collected each time a patient uses the experience to consider the effect repeat exposure has on wellbeing and symptoms. 0 = No symptoms to 10 = Worst Symptom

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026